Abstract
Sirtuins family is a class of NDA+ dependent protein deacetylases that play a key role in the regulation of several aspects of biological processes, such as cell cycle regulation, autophagy, immune and inflammatory response. Many studies have shown that sirtuins2 as a key player in the cancer pathway is of great significance in tumorigenesis. This review summarizes the newly discovered, in recent years, some SIRT2 inhibitors for cancer target structure, action mechanism, biological activity, substrate specificity, and signaling pathways.
Keywords: Sirtuins, Sirt2 inhibitor, Substrate, Signaling pathways, Cancer, N-terminal.
Graphical Abstract
[1]
Wolffe, A.; Matzke, M. Epigenetics: Regulation through repression. Science, 1999, 286(5439), 481-486. [http:// dx.doi.org/10.11226/science.286.5439.481]. [PMID: 10521337].
[2]
Chaturvedi, P.; Tyagi, S.C. Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int. J. Cardiol., 2014, 173(1), 1-11. [http://dx.doi.org/10.1016/j.ijcard.2014.02.008]. [PMID: 24636549].
[3]
Chalkiadaki, A.; Guarente, L. The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer, 2015, 15(10), 608-624. [http://dx.doi.org/10.1038/nrc3985]. [PMID: 26383140].
[4]
Shuang, S.; Zeming, L.U.; Jin, J.J.; Yong, C. Genetic modes of epigenetic modification and its research progress. Chin. Sci. Bull., 2016, 61(36), 3878-3886. [http://dx.doi.org/10.1360/N972016-00972].
[5]
Chalkiadaki, A.; Guarente, L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol., 2012, 8(5), 287-296. [http://dx.doi.org/10.1038/nrendo.2011.225]. [PMID: 22249520].
[6]
Chang, H.C.; Guarente, L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab., 2014, 25(3), 138-145. [http://dx.doi.org/10.1016/j.tem.2013.12.001]. [PMID: 24388149].
[7]
Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; Ito, H.; Oshimura, M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene, 2007, 26(7), 945-957. [http://dx.doi.org/10.1038/sj.onc.1209857]. [PMID: 16909107].
[8]
Xiaobo, M. Design, Synthesis and Activity of A Novel Selective Epigenetic Target SIRT2 Inhibitor; Xihua University: Chengdu, 2017.
[9]
Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784. [http://dx.doi.org/10.1038/nrd2133]. [PMID: 16955068].
[10]
Haigis, M.C.; Sinclair, D.A. Mammalian sirtuins: Biological insights and disease relevance. Annu. Rev. Pathol., 2010, 5, 253-295. [http://dx.doi.org/10.1146/annurev.pathol.4.110807.092250]. [PMID: 20078221].
[11]
Michan, S.; Sinclair, D. Sirtuins in mammals: Insights into their biological function. Biochem. J., 2007, 404(1), 1-13. [http://dx.doi.org/10.1042/BJ20070140]. [PMID: 17447894].
[12]
Moniot, S.; Weyand, M.; Steegborn, C. Structures, substrates, and regulators of Mammalian sirtuins - opportunities and challenges for drug development. Front. Pharmacol., 2012, 3(3), 16. [http://dx.doi.org/10.3389/fphar.2012.00016]. [PMID: 22363286].
[13]
Chopra, V.; Quinti, L.; Kim, J.; Vollor, L.; Narayanan, K.L.; Edgerly, C.; Cipicchio, P.M.; Lauver, M.A.; Choi, S.H.; Silverman, R.B.; Ferrante, R.J.; Hersch, S.; Kazantsev, A.G. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep., 2012, 2(6), 1492-1497. [http://dx.doi.org/10.1016/j.celrep.2012.11.001]. [PMID: 23200855].
[14]
Gomes, P.; Fleming Outeiro, T.; Cavadas, C. Emerging Role of Sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol. Sci., 2015, 36(11), 756-768. [http://dx.doi.org/10.1016/j.tips.2015.08.001]. [PMID: 26538315].
[15]
Liu, G.; Park, S.H.; Imbesi, M.; Nathan, W.J.; Zou, X.; Zhu, Y.; Jiang, H.; Parisiadou, L.; Gius, D. Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy. Antioxid. Redox Signal., 2017, 26(15), 849-863. [http://dx.doi.org/10.1089/ars.2016.6662]. [PMID: 27460777].
[16]
Kozako, T.; Suzuki, T.; Yoshimitsu, M.; Arima, N.; Honda, S.; Soeda, S. Anticancer agents targeted to sirtuins. Molecules, 2014, 19(12), 20295-20313. [http://dx.doi.org/10.3390/molecules191220295]. [PMID: 25486244].
[17]
Wang, F.; Nguyen, M.; Qin, F.X.; Tong, Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell, 2007, 6(4), 505-504. [http://dx.doi.org/10.1111/j.1474-9726.2007.00304.x].
[18]
Kim, H.S.; Vassilopoulos, A.; Wang, R.H.; Lahusen, T.; Xiao, Z.; Xu, X.; Li, C.; Veenstra, T.D.; Li, B.; Yu, H.; Ji, J.; Wang, X.W.; Park, S.H.; Cha, Y.I.; Gius, D.; Deng, C.X. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell, 2011, 20(4), 487-499. [http://dx.doi.org/10.1016/j.ccr.2011.09.004]. [PMID: 22014574].
[19]
Maxwell, M.M.; Tomkinson, E.M.; Nobles, J.; Wizeman, J.W.; Amore, A.M.; Quinti, L.; Chopra, V.; Hersch, S.M.; Kazantsev, A.G. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet., 2011, 20(20), 3986-3996. [http://dx.doi.org/10.1093/hmg/ddr326]. [PMID: 21791548].
[20]
Hu, F.; Sun, X.; Li, G.; Wu, Q.; Chen, Y.; Yang, X.; Luo, X.; Hu, J.; Wang, G. Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway. Cell Death Dis., 2018, 10(1), 9. [http://dx.doi.org/10.1038/s41419-018-1260-z]. [PMID: 30584257].
[21]
Huang, S.; Zhao, Z.; Tang, D.; Zhou, Q.; Li, Y.; Zhou, L.; Yin, Y.; Wang, Y.; Pan, Y.; Dorfman, R.G.; Ling, T.; Zhang, M. Downregulation of sirt2 inhibits invasion of hepatocellular carcinoma by inhibiting energy metabolism. Transl. Oncol., 2017, 10(6), 917-927. [http://dx.doi.org/10.1016/j.tranon.2017.09.006]. [PMID: 28992545].
[22]
Kim, H.S.; Vassilopoulos, A.; Wang, R.H.; Lahusen, T.; Xiao, Z.; Xu, X.; Li, C.; Veenstra, T.D.; Li, B.; Yu, H.; Ji, J.; Wang, X.W.; Park, S.H.; Cha, Y.I.; Gius, D.; Deng, C.X. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell, 2011, 20(4), 487-499. [http://dx.doi.org/10.1016/j.ccr.2011.09.004]. [PMID: 22014574].
[23]
McGlynn, L.M.; Zino, S.; MacDonald, A.I.; Curle, J.; Reilly, J.E.; Mohammed, Z.M.A.; McMillan, D.C.; Mallon, E.; Payne, A.P.; Edwards, J.; Shiels, P.G. SIRT2: Tumour suppressor or tumour promoter in operable breast cancer? Eur. J. Cancer, 2014, 50(2), 290-301. [http://dx.doi.org/10.1016/j.ejca.2013.10.005]. [PMID: 24183459].
[24]
Soung, Y.H.; Pruitt, K.; Chung, J. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Sci. Rep., 2014, 4(19)(Suppl.), 3846. [PMID: 24457910].
[25]
Cheon, M.G.; Kim, W.; Choi, M.; Kim, J.E. AK-1, A specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett., 2015, 356(2 Pt B), 637-645. [http://dx.doi.org/10.1016/j.canlet.2014.10.012]. [PMID: 25312940].
[26]
Yan-Hua, D.U.; Zhang, H.Y.; Sun, H.; Amp, O. Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation,migration and invasion. Chinese J. Pathophysiol., 2015, 11(10), 1181-1189.
[27]
Jing, H.; Hu, J.; He, B.; Negrón Abril, Y.L.; Stupinski, J.; Weiser, K.; Carbonaro, M.; Chiang, Y.L.; Southard, T.; Giannakakou, P.; Weiss, R.S.; Lin, H.A. SIRT2-selective inhibitor promotes c-myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell, 2016, 29(3), 297-310. [http://dx.doi.org/10.1016/j.ccell.2016.02.007]. [PMID: 26977881].
[28]
Singh, S.; Kumar, P.U.; Thakur, S.; Kiran, S.; Sen, B.; Sharma, S.; Rao, V.V.; Poongothai, A.R.; Ramakrishna, G. Expression/locali-zation patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells. Tumour Biol., 2015, 36(8), 6159-6171. [http://dx.doi.org/10.1007/s13277-015-3300-y]. [PMID: 25794641].
[29]
Kim, H.W.; Kim, S.A.; Ahn, S.G. Sirtuin inhibitors, EX527 and AGK2, suppress cell migration by inhibiting HSF1 protein stability. Oncol. Rep., 2016, 35(1), 235-242. [http://dx.doi.org/10.3892/or.2015.4381]. [PMID: 26530275].
[30]
He, X.; Nie, H.; Hong, Y.; Sheng, C.; Xia, W.; Ying, W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem. Biophys. Res. Commun., 2012, 417(1), 468-472. [http://dx.doi.org/10.1016/j.bbrc.2011.11.141]. [PMID: 22166219].
[31]
Grbesa, I.; Pajares, M.J.; Martínez-Terroba, E.; Agorreta, J.; Mikecin, A.M.; Larráyoz, M.; Idoate, M.A.; Gall-Troselj, K.; Pio, R.; Montuenga, L.M. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One, 2015, 10(4)e0124670 [http://dx.doi.org/10.1371/journal.pone.0124670]. [PMID: 25915617].
[32]
Dryden, S.C.; Nahhas, F.A.; Nowak, J.E.; Goustin, A.S.; Tainsky, M.A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol., 2003, 23(9), 3173-3185. [http://dx.doi.org/10.1128/MCB.23.9.3173-3185.2003]. [PMID: 12697818].
[33]
Seo, K.S.; Park, J.H.; Heo, J.Y.; Jing, K.; Han, J.; Min, K.N.; Kim, C.; Koh, G.Y.; Lim, K.; Kang, G.Y.; Uee Lee, J.; Yim, Y.H.; Shong, M.; Kwak, T.H.; Kweon, G.R. SIRT2 regulates tumour hypoxia response by promoting HIF-1α hydroxylation. Oncogene, 2015, 34(11), 1354-1362. [http://dx.doi.org/10.1038/onc.2014.76]. [PMID: 24681946].
[34]
Suematsu, T.; Li, Y.; Kojima, H.; Nakajima, K.; Oshimura, M.; Inoue, T. Deacetylation of the mitotic checkpoint protein BubR1 at lysine 250 by SIRT2 and subsequent effects on BubR1 degradation during the prometaphase/anaphase transition. Biochem. Biophys. Res. Commun., 2014, 453(3), 588-594. [http://dx.doi.org/10.1016/j.bbrc.2014.09.128]. [PMID: 25285631].
[35]
Hong, N.; Feng, Y.; Jing-Wen, T.; Tong-De, T.; Hua-Hua, L.I.; Guang-Xing, Y.; Yi-Xiao, F.; Hao-Ben, Z. Influences of SIRT2 silence on proliferation, migration and invasion of gastric cancer SGC-7901 cells. Chinese Med. Biotechnol., 2018, 13(6), 526-531.
[36]
Rumpf, T.; Schiedel, M.; Karaman, B.; Roessler, C.; North, B.J.; Lehotzky, A.; Oláh, J.; Ladwein, K.I.; Schmidtkunz, K.; Gajer, M.; Pannek, M.; Steegborn, C.; Sinclair, D.A.; Gerhardt, S.; Ovádi, J.; Schutkowski, M.; Sippl, W.; Einsle, O.; Jung, M. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat. Commun., 2015, 6(2382), 6263. [http://dx.doi.org/10.1038/ncomms7263]. [PMID: 25672491].
[37]
Jing, H.; Zhang, X.; Wisner, S.A.; Chen, X.; Spiegelman, N.A.; Linder, M.E.; Lin, H. SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. eLife, 2017, 6, 32. [http://dx.doi.org/10.7554/eLife.32436]. [PMID: 29239724].
[38]
Du, J.; Zhou, Y.; Su, X.; Yu, J.J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J.H.; Choi, B.H.; He, B.; Chen, W.; Zhang, S.; Cerione, R.A.; Auwerx, J.; Hao, Q.; Lin, H. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science, 2011, 334(6057), 806-809. [http://dx.doi.org/10.1126/science.1207861]. [PMID: 22076378].
[39]
Mathias, R.A.; Greco, T.M.; Oberstein, A.; Budayeva, H.G.; Chakrabarti, R.; Rowland, E.A.; Kang, Y.; Shenk, T.; Cristea, I.M. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell, 2014, 159(7), 1615-1625. [http://dx.doi.org/10.1016/j.cell.2014.11.046]. [PMID: 25525879].
[40]
Tan, M.; Peng, C.; Anderson, K.A.; Chhoy, P.; Xie, Z.; Dai, L.; Park, J.; Chen, Y.; Huang, H.; Zhang, Y.; Ro, J.; Wagner, G.R.; Green, M.F.; Madsen, A.S.; Schmiesing, J.; Peterson, B.S.; Xu, G.; Ilkayeva, O.R.; Muehlbauer, M.J.; Braulke, T.; Mühlhausen, C.; Backos, D.S.; Olsen, C.A.; McGuire, P.J.; Pletcher, S.D.; Lombard, D.B.; Hirschey, M.D.; Zhao, Y. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab., 2014, 19(4), 605-617. [http://dx.doi.org/10.1016/j.cmet.2014.03.014]. [PMID: 24703693].
[41]
Hoffmann, G.; Breitenbücher, F.; Schuler, M.; Ehrenhofer-Murray, A.E. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem., 2014, 289(8), 5208-5216. [http://dx.doi.org/10.1074/jbc.M113.487736]. [PMID: 24379401].
[42]
Ma, W.; Zhao, X.; Wang, K.; Liu, J.; Huang, G. Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer. Cancer Biol. Ther., 2018, 19(9), 835-846. [http://dx.doi.org/10.1080/15384047.2018.1480281]. [PMID: 30067423].
[43]
Zhao, D.; Mo, Y.; Li, M.T.; Zou, S.W.; Cheng, Z.L.; Sun, Y.P.; Xiong, Y.; Guan, K.L.; Lei, Q.Y. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J. Clin. Invest., 2014, 124(12), 5453-5465. [http://dx.doi.org/10.1172/JCI76611]. [PMID: 25384215].
[44]
Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B.J.; Viollet, B.; Mamer, O.A.; Avizonis, D.; DeBerardinis, R.J.; Siegel, P.M.; Jones, R.G. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab., 2013, 17(1), 113-124. [http://dx.doi.org/10.1016/j.cmet.2012.12.001]. [PMID: 23274086].
[45]
Mungai, P.T.; Waypa, G.B.; Jairaman, A.; Prakriya, M.; Dokic, D.; Ball, M.K.; Schumacker, P.T. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol. Cell. Biol., 2011, 31(17), 3531-3545. [http://dx.doi.org/10.1128/MCB.05124-11]. [PMID: 21670147].
Call for Papers in Thematic Issues
24 September, 2024
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
28 July, 2024
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
13 August, 2024
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
31 December, 2024
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Botanicals and Natural Bioactives: Prevention and Treatment of Diseases
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers In Medicinal Chemistry
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Frontiers in Natural Product Chemistry
Article Metrics
113
9
1
